Details for Patent: 12,447,169
✉ Email this page to a colleague
Which drugs does patent 12,447,169 protect, and when does it expire?
Patent 12,447,169 protects LIVTENCITY and is included in one NDA.
Summary for Patent: 12,447,169
| Title: | Maribavir isomers, compositions, methods of making and methods of using |
| Abstract: | The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs. |
| Inventor(s): | John D. Peabody, III |
| Assignee: | Takeda Pharmaceutical Co Ltd |
| Application Number: | US18/828,652 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 12,447,169
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | LIVTENCITY | maribavir | TABLET;ORAL | 215596-001 | Nov 23, 2021 | RX | Yes | Yes | 12,447,169 | ⤷ Start Trial | TREATMENT OF PATIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR, OR FOSCARNET, BY ADMINISTERING 400 MG OF MARIBAVIR ORALLY TWICE DAILY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
